Scynexis (SCYX) Total Liabilities (2013 - 2026)
Scynexis' (SCYX) quarterly Total Liabilities came in at $8.0 million in Q2 2026, down 50.45% on a YoY basis from $16.2 million in Q2 2025, and down 77.86% quarter-over-quarter from $36.3 million in Q1 2026.
Analysis
Scynexis (SCYX) Total Liabilities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Total Liabilities for 14 consecutive years, with $8.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Liabilities fell 50.45% year-over-year to $8.0 million; the trailing twelve-month figure through Jun 2026 stood at $8.0 million (down 50.45% YoY), and the FY2025 full-year result was $9.7 million, down 72.86% from the prior year.
- Total Liabilities eased to $8.0 million in Q2 2026 per SCYX's latest filing, from $36.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $100.2 million in Q1 2023 and bottomed at $8.0 million in Q2 2026.
- Historically, Total Liabilities has averaged $49.2 million across 5 years, with a median of $45.8 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities slumped 72.86% in 2025, then surged 108.93% in 2026.
- Over 5 years, Total Liabilities stood at $84.6 million in 2022, then slumped by 34.44% to $55.4 million in 2023, then plunged by 35.86% to $35.6 million in 2024, then slumped by 72.86% to $9.7 million in 2025, then retreated by 16.69% to $8.0 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $8.0 million, $36.3 million, and $9.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 8.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.04 Mn |
| Mar 31, 2026 | 36.32 Mn |
| Dec 31, 2025 | 9.65 Mn |
| Sep 30, 2025 | 14.64 Mn |
| Jun 30, 2025 | 16.23 Mn |
| Mar 31, 2025 | 17.38 Mn |
| Dec 31, 2024 | 35.57 Mn |
| Sep 30, 2024 | 40.51 Mn |
| Jun 30, 2024 | 47.40 Mn |
| Mar 31, 2024 | 44.15 Mn |
| Dec 31, 2023 | 55.45 Mn |
| Sep 30, 2023 | 56.56 Mn |
| Jun 30, 2023 | 61.78 Mn |
| Mar 31, 2023 | 100.21 Mn |
| Dec 31, 2022 | 84.58 Mn |
| Sep 30, 2022 | 95.08 Mn |
| Jun 30, 2022 | 90.13 Mn |
| Mar 31, 2022 | 72.64 Mn |
| Dec 31, 2021 | 78.58 Mn |
| Sep 30, 2021 | 72.27 Mn |